Viewing

News

Jonathan S. Myers, MD, reports that intraocular drug delivery systems could help solve the problem of poor adherence in patients taking glaucoma medications. Implanted in the eye, the systems would allow for glaucoma drugs to gradually dissolve or elute medication.

The development of many innovations in ophthalmology did not happen in a straightforward manner as shown in these case examples.

Two headlines broke new ground recently when it comes to horror and adversity. Coincidentally, they both involved worms and left eyes: "Woman pulls wiggling cattle worms from her eyeball, makes medical history" appeared along with "Brain-eating pork worm removed from man's eye."

Despite a heightened atmosphere on the Relative Value Scale Update Committee due to Congressional mandates to reallocate funds from specialty codes, ophthalmologists have been spared from the significant financial impact affecting certain other specialties. However, a number of important ophthalmic codes have been placed under review, leading to decreases in payment for some procedures.

A prototype of a novel dual-mode, accommodating-disaccommodating intraocular lens with zonular capture haptics has been fabricated successfully. The lens has shown in bench studies to exhibit axial shift and shape change that results in up to about 26 D of accommodative change,

Steven Vold, MD, reports that toric IOLs provide an accurate, safe, and convenient way to correct astigmatism and uncorrected distance vision for glaucoma patients, while patients wanting presbyopic correction have IOL options to fit a range of visual needs.

The Medicare Access and CHIP Reauthorization Act of 2015 and its Merit Based Incentive Payments System are here to stay for the foreseeable future and are likely to significantly impact reimbursement for ophthalmologists as part of a shift away from traditional fee for service medicine. In this changing landscape, eye care practitioners need to understand the basics of the system, such as reporting requirements, and begin to consider new models of care.

My classmate in medical school, Eric, only became a medical student because his father insisted. Eric wasn’t happy about this until he discovered he loved ophthalmology. He went on to perform brilliantly as a resident and built an extremely successful and fulfilling practice. Eric’s story is not unique.

One laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.

Research aiming to elucidate the underlying factors for oxidative damage to the trabecular meshwork in glaucoma has led to studies of alterations in gene expression that may ultimately guide the development of genetic therapy for glaucoma, said Carla J. Siegfried, MD, recipient of the 2018 Shaffer Prize for Innovative Glaucoma Research.

One laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.

In addition to making use of MIGS, interventional glaucoma might utilize other novel drainage devices and sustained drug-delivery devices and be combined with cataract surgery. This approach is more proactive, aims at lower IOP, lowers risk and addresses adherence, said Iqbal Ike K. Ahmed, MD.

Glaucoma 360, a three-day event being held here by the Glaucoma Research Foundation (GRF), will move from its "Celebrate" phase with Annual Gala on Thursday into its "Innovate" phase with the New Horizons Forum set for today. This event is a full day of presentations, panels, and discussions featuring leaders from start-up companies, industry executives, ophthalmic experts, venture capitalists, and the FDA.

Glaucoma 360, a three-day event organized by the Glaucoma Research Foundation (GRF) will move into its final day on Saturday with the Glaucoma Symposium. The focus will shift from "Innovate" to "Educate." Two continuing medical education sessions are-one for ophthalmologists in the morning and another for optometrists in the afternoon.